


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> Date Submitted: November 4, 2008 <i>(use as many sheets as necessary)</i>			<b>Complete if Known</b>	
Sheet 1 of 6			Application Number	10/031,145
			Filing Date	8/10/2000
			First Named Inventor	Nicole Zitzmann
			Art Unit	1617
			Examiner Name	Kathrien Ann Cruz
			Attorney Docket Number	080618-0241



U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	A1	2006/0106065 A1	05/18/2006	Jacob et al.	
	A2	2006/0252918 A1	11/2006	Rowlands et al.	
	A3	2006/0264468 A1	11/23/2006	Mueller et al.	
	A4	2006/0094671 A1	05/04/2006	Jacob et al.	
	A5	4,246,345	01/20/1981	Kinast et al.	
	A6	4,266,025	05/05/1981	Kinast et al.	
	A7	4,405,714	09/20/1983	Kinast et al.	
	A8	4,806,650	02/21/1989	Schröder et al.	
	A9	4,861,892	08/29/1989	Fleet	
	A10	4,894,388	01/16/1990	Fleet	
	A11	4,910,310	03/20/1990	Campbell et al.	
	A12	4,944,572	07/31/1990	Young	
	A13	4,996,329	02/26/1991	Fleet et al.	
	A14	5,011,929	04/30/1991	Fleet et al.	
	A15	5,013,842	05/07/1991	Fleet et al.	
	A16	5,017,704	05/21/1991	Fleet et al.	
	A17	5,043,273	08/27/1991	Scudder et al.	
	A18	5,100,797	03/31/1992	Fleet et al.	
	A19	5,103,008 A	04/07/1992	Scudder et al.	
	A20	5,200,523	04/06/1993	Fleet	
	A21	5,264,356 A	11/23/1993	Rohrschneider	
	A22	5,286,877	02/15/1994	Behling et al.	
	A23	5,310,745	05/10/1994	Partis et al.	
	A24	5,401,645 A	03/28/1995	Grabner et al.	
	A25	5,580,884	12/03/1996	Platt et al.	
	A26	5,596,005 A	01/21/1997	Wong et al.	
	A27	5,622,972	04/22/1997	Bryant et al.	
	A28	5,643,888 A	07/01/1997	Rohrschneider	
	A29	6,291,657 B1	09/18/2001	Platt et al.	
	A30	6,355,413 B1	03/12/2002	Gage et al.	
	A31	6,465,487 B1	10/15/2002	Block et al.	
	A32	6,465,488 B1	10/15/2002	Butters et al.	
	A33	6,545,021 B1	04/08/2003	Mueller et al.	
	A34	6,660,749 B2	12/09/2003	Butters et al.	
	A35	6,689,759 B1	02/10/2004	Jacob et al.	
	A36	6,809,083 B1	10/26/2004	Mueller et al.	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> Date Submitted: November 4, 2008 (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/031,145
				Filing Date	8/10/2000
				First Named Inventor	Nicole Zitzmann
				Art Unit	1617
				Examiner Name	Kathrien Ann Cruz
				Attorney Docket Number	080618-0241
Sheet	2	of	6		

UNPUBLISHED U.S. PATENT APPLICATION DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Application Document	Filing Date of Cited Document MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Serial Number-Kind Code <sup>2</sup> (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	A37	EP 0 367 747 A	05/09/1990	G.D. Searle & Company		
	A38	EP 0 445 098 A2	02/25/1991	G.D. Searle & Company		
	A39	WO 98/35685 A1	08/20/1998	G.D. Searle & Company		
	A40	WO 99/24401 A1	05/20/1999	G.D. Searle & Company		
	A41	WO 99/40916 A1	08/19/1999	G.D. Searle & Co.		
	A42	WO 00/47198 A2	08/17/2000	G.D. Searle & Company		
	A43	WO 01/60366 A1	08/23/2001	Pharmacia Corporation		
	A44	WO 2004/005333 A1	01/15/2004	University of Leeds		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	A45	ACOSTA et al., "Agents for treating human immunodeficiency virus infection," Am. J. Hosp. Pharm., September 15, 1994, 51:2251-2267.	
	A46	BERGE et al., "Pharmaceutical Salts," J. Pharm. Sci., January 1977, 66(1):1-19.	
	A47	BERGERON et al., "Calnexin: a membrane-bound chaperone of the endoplasmic reticulum," TIBS 19 - March 1994, Elsevier Scient Ltd. 0968-0004/94 pp. 124-128.	
	A48	BLOCK et al., "Secretion of human hepatitis B virus is inhibited by the imino sugar N-butyldeoxynojirimycin," PNAS, March 1994, 91:2235-2239.	
	A49	BLUM et al., "Antiviral therapy of hepatitis B virus infection: Blocking viral gene expression," Advanced Drug Delivery Reviews, 1995, 17:321-331.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted: November 4, 2008 <i>(use as many sheets as necessary)</i>		<b>Complete if Known</b>	
		Application Number	10/031,145
		Filing Date	8/10/2000
		First Named Inventor	Nicole Zitzmann
		Art Unit	1617
		Examiner Name	Kathrien Ann Cruz
Sheet	3	of	6
		Attorney Docket Number	080618-0241

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	A50	BRANZA-NICHITA et al., "Antiviral of N-Butyledeoxynojirimycin against Bovine Viral Diarrhea Virus Coorelates with Misfolding of E2 Envelope Proteins and Impairment of Their Association into E1-E2 Heterodimers," (2001) J. Virol. 75(8), pp. 3527-36.	
	A51	BRUSS et al., "The role of envelope proteins in hepatitis B virus assembly, PNAS, February 1991, 88:1059-1063.	
	A52	CARRÈRE-KREMER et al., "Subcellular Localization and Topology of the p7 Polypeptide of Hepatitis C Virus," Journal of Virology, April 2002, 76(8) :3720-3730.	
	A53	CHOUKHI et al., "Involvement of Endoplasmic Reticulum Chaperones in the Folding of Hepatitis C Virus Glycoproteins, (1998) J. Virol., 72(5), pp. 3851-8.	
	A54	COATES et al., "Developments in viral hepatitis during 1994," Exp. Opin. Ther. Patents, 1995, 5(8):747-756.	
	A55	COURAGEOT et al., "a-Glucosidase Inhibitors Reduce Dengue Virus Production by Affecting the Initial Steps of Virion Morphogenesis in the Endoplasmic Reticulum," (2000) J. Virol., 74(1): pp. 564-72.	
	A56	DE FRANCESCO et al., "Biochemical and immunologic properties of the nonstructural proteins of the hepatitis C virus: implications for development of antiviral agents and vaccines," Semin. Liver Dis., 2000, 20(1):69-83, one page Abstract only.	
	A57	DI BISCEGLIE, Adrian M., "Hepatitis C and Hepatocellular Carcinoma," Hepatology, September 1997, 26(3)Suppl. 1:345-350.	
	A58	DOONG et al., "Inhibition of the replication of hepatitis B virus <i>in vitro</i> by 2',3'-dideoxy-3'-thiacytidine and related analogues," PNAS, October 1991, 88:8495-8499.	
	A59	DUFF et al., "The Transmembrane Domain of Influenza A M2 Protein Forms Amantadine-Sensitive Proton Channels in Planar Lipid Bilayers," Virology 190, pp. 485-489 (1992) 0042-6822/92 Copyright 1992 by Academic Press, Inc.	
	A60	DURANTEL et al., "Study of the Mechanism of Antiviral Action of Iminosugar Derivatives against Bovine Viral Diarrhea Virus," (2001) J. Virol. 75(19): pp. 8987-98.	
	A61	DWEK, et al., "Targeting Glycosylation as a Therapeutic Approach," Nature Reviews/Drug Discovery, Vol. 1, January 2002, pp. 65-75. Glycobiology Institute, Dept. of Biochemistry, University of Oxford, Oxford OX1 3QU, UK.	
	A62	ELBEIN et al., "Inhibitors of the biosynthesis and processing of N-linked oligosaccharide chains," Ann. Rev. Biochem., 1987, 56:497-534.	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted: November 4, 2008 <i>(use as many sheets as necessary)</i>		<b>Complete if Known</b>	
		Application Number	10/031,145
		Filing Date	8/10/2000
		First Named Inventor	Nicole Zitzmann
		Art Unit	1617
		Examiner Name	Kathrien Ann Cruz
Sheet	4	of	6
		Attorney Docket Number	080618-0241

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	A63	ESPOSITO et al., "Synthesis of amphiphilic polyhydroxylated pyrrolidones as potential glycosidase inhibitors," Tetrahedron Lett., 1998, 39(36):6543-6546.	
	A64	FISCHER et al., "Amantadine blocks channel activity of the transmembrane segment of the NB protein from influenza B," Eur. Biophys J. (2001) 30: pp. 416-420, DOI 10.1007/s00240100157.	
	A65	FLEET et al., "Enantiospecific synthesis of deoxymannojirimycin, fagomine and 2R,5R-dihydroxymethyl-3R,4R-dihydroxypyrrolidine from D-glucose," Tetrahedron Letters, 1985, 26(11):1469-1472.	
	A66	FOUREL et al., "The Carbocyclic Analog of 2'-Deoxyguanosine Induces a Prolonged Inhibition of Duck Hepatitis B Virus DNA Synthesis in Primary Hepatocyte Cultures and in the Liver," J. Virol., February 1994, 68(2):1059-1065.	
	A67	GABRIELSON et al., "Synthesis and Antiviral Evaluation of N-Carboxamidine-Substituted Analogues of 1-β-D-Ribofuranosyl-1,2,4-triazole-3-carboxamidine Hydrochloride," J. Med. Chem., 1992, 35:3231-3238.	
	A68	GANEM, D., "Assembly of Hepadnaviral Virions and Subviral Particles," Curr. Top. Microbiol. Immunol., 1991, 168:61-83.	
	A69	GRIFFIN et al., "A conserved basic loop in hepatitis C virus p7 protein is required for amantidine-sensitive ion channel activity in mammalian cells but is dispensable for localization to mitochondria," Journal of General Virology, 2004, 85:451-461.	
	A70	GRIFFIN et al., "The p7 protein of hepatitis C virus forms an ion channel that is blocked by the antiviral drug, Amantadine," FEBS Letters 535 (2003) pp. 34-38, Elsevier Science B.V. on behalf of the Federation of European Biochemical Societies.	
	A71	GUIDOTTI et al., "Interleukin-2 and Alpha/Beta Interferon Down-Regulate Hepatitis B Virus Gene Expression In Vivo by Tumor Necrosis Factor-Dependent and -Independent Pathways," J. Virol., March 1994, 68(3):1265-1270.	
	A72	HARADA et al., "E2-p7 Region of the Bovine Viral Diarrhea Virus Polypeptide: Processing and Functional Studies," (2000) J. Virol. 74(20): pp. 9498-506.	
	A73	HAY et al., "The molecular basis of the specific anti-influenza action of amantadine," EMBO Journal, Vol. 4 no. 11 pp. 3021-3024, 1985. 'Oxford, England.	
	A74	HENZLER et al., "Avoiding viral contamination in biotechnological and pharmaceutical processes," Nature Biotechnology, November 1998, 16:1077-1078.	
	A75	HOOFNAGLE et al., "The Treatment of Chronic Viral Hepatitis," New Engl. J. Med., January 30, 1997, 336(5):347-356.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted: November 4, 2008 (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/031,145
		Filing Date	8/10/2000
		First Named Inventor	Nicole Zitzmann
		Art Unit	1617
		Examiner Name	Kathrien Ann Cruz
Sheet	5	of	6
		Attorney Docket Number	080618-0241

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	A76	LIN et al., "Processing in the Hepatitis C Virus E2-NS2 Region: Identification of p7 and Two Distinct E2-Specific Products with Different C Termini," (1994) J. Virol. 68(8): pp. 5063-73.	
	A77	LOCARNINI et al., "Hepatitis B: New approaches for antiviral chemotherapy," Antiviral Chemistry & Chemotherapy, 1996, 7(2):53-64.	
	A78	LOHMANN et al., "Replication of Subgenomic Hepatitis C Virus RNAs in a Hepatoma Cell Line," (1999) Science, 285(5424) pp. 110-3.	
	A79	LU et al., "Aberrant trafficking of hepatitis B virus glycoproteins in cells in which N-glycan processing is inhibited," PNAS, March 1997, 94:2380-2385.	
	A80	MARTIN et al., "Pilot Study of Recombinant Human Granulocyte-macrophage Colony-stimulating Factor in the Treatment of Chronic Hepatitis B," Hepatology, October 1993, 18(4):778-780.	
	A81	MEHTA et al., "a-Glucosidase inhibitors as potential broad based anti-viral agents," FEBS Lett. 1998 June 23; 430(1-2); pp. 17-22.	
	A82	MEHTA et al., "Hepatitis B virus (HBV) envelope glycoproteins vary drastically in their sensitive to glycan processing: Evidence that alteration of a single N-linked glycosylation site can regulate HBV secretion," PNAS, March 1997, 94:1822-1827.	
	A83	MILLER et al., "Hepatitis C virus shares amino acid sequence similarity with pestiviruses and flaviviruses as well as members of two plant virus supergroups," PNAS, March 1990, 87:2057-2061.	
	A84	MIZUSHIMA et al., "Two Hepatitis C Virus Glycoprotein E2 Products with Different C Termini," (1994) J. Virol. 68(10); pp. 6215-22.	
	A85	MONTAL et al., "Formation of Bimolecular Membranes from Lipid Monolayers and a Study of Their Electrical Properties," Proc. Nat. Acad. Sci. USA 69 (1972) pp. 3561-3566.	
	A86	PAVLOVIC et al., "The hepatitis C virus p7 protein forms an ion channel that is inhibited by long-alkyl-chain iminosugar derivatives," PNAS 2003, May 13; 100(10): pp. 6104-8.	
	A87	PETERSON et al., "Transient, Lectin-like Association of Calreticulin with Folding Intermediates of Cellular and Viral Glycoproteins," Molecular Biology of the Cell, Vol. 6, pp. 1173-1184, September 1995 by The American Society for Cell Biology.	
	A88	PIETSCHMANN et al., "Characterization of Cell Lines Carrying Self-Replicating Hepatitis C Virus RNAs," (2001) J. Virol. 75(3); pp. 1252-64.	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted: November 4, 2008  (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/031,145
		Filing Date	8/10/2000
		First Named Inventor	Nicole Zitzmann
		Art Unit	1617
		Examiner Name	Kathrien Ann Cruz
Sheet	6	of	6
		Attorney Docket Number	080618-0241

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	A89	REED et al., "Overview of Hepatitis C Virus Genome Structure, Polyprotein Processing, and Protein Properties," Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, pp. 55-84.	
	A90	ROKITSKAYA et al., "Effect of Avidin on Channel Kinetics of Biotinylated Gramicidin," Biochemistry, 2000, 39:13053-13058.	
	A91	SAKAI et al., "The p7 polypeptide of hepatitis C virus is critical for infectivity and contains functionally important genotype-specific sequences," PNAS, September 30, 2003, 100(20):11646-11651.	
	A92	SAUNIER et al., "Inhibition of N-linked Complex Oligosaccharide Formation by 1-Deoxynojirimycin, and Inhibitor of Processing Glucosidases," J. Biol. Chem., December 1982, 257(23):14155-14161.	
	A93	SMITH JP, "Treatment of chronic hepatitis C with amantadine," Dig. Dis. Sci., August 1997, 42(8):1681-1687, one page Abstract only.	
	A94	SULLIVAN et al., "A nested polymerase chain reaction assay to differentiate pestiviruses," Virus Res., 1995, 38:231-239.	
	A95	SUNSTROM, et al., "Ion Channels Formed by NB, an Influenza B Virus Protein," J. Membrane Biol. 150, pp. 127-132 (1996).	
	A96	SWARTZ et al., "An Inhibitor of the Kv2.1 Potassium Channel Isolated from the Venom of a Chilean Tarantula," Neuron, October 1996, 15:941-948.	
	A97	VAN DEN BROEK et al., "Chemical modification of azasugars, inhibitors of N-glycoprotein-processing glycosidases and of HIV-1 infection," Recl. Trav. Chim. Pays-Bas, 1993, 112:82-94.	
	A98	WU et al., "Antiviral Effects of an Iminosugar Derivative on Flavivirus Infections," (2002) J. Virol., 76(8): pp. 3596-604.	
	A99	XU et al., "Synthesis of a novel hepatitis C virus protein by ribosomal frameshift," (2001) The EMBO Journal 20(14): pp. 3840-8.	
	A100	ZITZMANN, et al., "Imino sugars inhibit the formation and secretion of bovine viral diarrhea virus, a pestivirus model of hepatitis C virus: Implications for the development of broad spectrum anti-hepatitis virus agents," PNAS, Oct. 12, 1991, 96(21):11878-11882.	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.